Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.2751
+0.0193 (7.54%)
At close: Apr 15, 2026, 4:00 PM EDT
0.2752
+0.0001 (0.04%)
After-hours: Apr 15, 2026, 7:59 PM EDT
Sangamo Therapeutics Revenue
In the year 2025, Sangamo Therapeutics had annual revenue of $39.55M, down -31.57%. Sangamo Therapeutics had revenue of $14.23M in the quarter ending December 31, 2025, with 88.43% growth.
Revenue (ttm)
$39.55M
Revenue Growth
-31.57%
P/S Ratio
2.88
Revenue / Employee
$278,535
Employees
142
Market Cap
113.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.55M | -18.25M | -31.57% |
| Dec 31, 2024 | 57.80M | -118.43M | -67.20% |
| Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
| Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
| Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
| Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
| Dec 31, 2019 | 102.43M | 17.98M | 21.29% |
| Dec 31, 2018 | 84.45M | 47.89M | 130.95% |
| Dec 31, 2017 | 36.57M | 17.18M | 88.60% |
| Dec 31, 2016 | 19.39M | -20.15M | -50.96% |
| Dec 31, 2015 | 39.54M | -6.33M | -13.80% |
| Dec 31, 2014 | 45.87M | 21.74M | 90.07% |
| Dec 31, 2013 | 24.13M | 2.48M | 11.44% |
| Dec 31, 2012 | 21.66M | 11.34M | 109.86% |
| Dec 31, 2011 | 10.32M | -10.49M | -50.40% |
| Dec 31, 2010 | 20.81M | -1.38M | -6.23% |
| Dec 31, 2009 | 22.19M | 6.00M | 37.08% |
| Dec 31, 2008 | 16.19M | 7.09M | 77.91% |
| Dec 31, 2007 | 9.10M | 1.21M | 15.38% |
| Dec 31, 2006 | 7.89M | 5.40M | 217.43% |
| Dec 31, 2005 | 2.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Seer, Inc. | 16.58M |
| Pyxis Oncology | 13.86M |
| Coya Therapeutics | 7.95M |
| Equillium | 4.39M |
| Cibus | 3.64M |
| Kazia Therapeutics | 1.27M |
| Cardiff Oncology | 593.00K |
| Genelux | 8.00K |
SGMO News
- 16 days ago - Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results - GlobeNewsWire
- 27 days ago - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call - GlobeNewsWire
- 5 weeks ago - Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering - GlobeNewsWire
- 4 months ago - Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - GlobeNewsWire
- 4 months ago - Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - GlobeNewsWire
- 5 months ago - Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - GlobeNewsWire